Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jason R, Todd"'
Autor:
Jocelyn P. Wong, Jason R. Todd, Martina A. Finetti, Frank McCarthy, Malgorzata Broncel, Simon Vyse, Maciej T. Luczynski, Stephen Crosier, Karen A. Ryall, Kate Holmes, Leo S. Payne, Frances Daley, Patty Wai, Andrew Jenks, Barbara Tanos, Aik-Choon Tan, Rachael C. Natrajan, Daniel Williamson, Paul H. Huang
Publikováno v:
Cell Reports, Vol 17, Iss 5, Pp 1265-1275 (2016)
Summary: Subunits of the SWI/SNF chromatin remodeling complex are mutated in a significant proportion of human cancers. Malignant rhabdoid tumors (MRTs) are lethal pediatric cancers characterized by a deficiency in the SWI/SNF subunit SMARCB1. Here,
Externí odkaz:
https://doaj.org/article/1ea3b596e8cc4e36bc647eff1eeb7332
Autor:
Helen Rizos, Georgina V. Long, Richard F. Kefford, Richard A. Scolyer, Adnan M. Nagrial, Mal Irvine, Suzanah C. Boyd, Jason R. Todd, Hamideh Shahheydari, Carina Fung, Matteo S. Carlino
Background: MEK1 mutations in melanoma can confer resistance to BRAF inhibitors, although preexisting MEK1P124 mutations do not preclude clinical responses. We sought to determine whether recurrent, preexisting MEK1P124 mutations affected clinical ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::110ab1548d00d020ff420f208f11de0c
https://doi.org/10.1158/1078-0432.c.6522786
https://doi.org/10.1158/1078-0432.c.6522786
Autor:
Helen Rizos, Georgina V. Long, Richard F. Kefford, Richard A. Scolyer, Adnan M. Nagrial, Mal Irvine, Suzanah C. Boyd, Jason R. Todd, Hamideh Shahheydari, Carina Fung, Matteo S. Carlino
Supplementary Figures 1-5. S1 MEK1 P124 variants activate ERK1/2; S2 MEK1P124Q diminishes BRAF inhibitor sensitivity; S3 Effect of MEK1 mutations on MAPK and PI3K pathway signaling; S4 Identification of MEK1P124Q variant in the SMU030 cell line; S5 C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::133911664742d3852007bcc120e15bbe
https://doi.org/10.1158/1078-0432.22454580.v1
https://doi.org/10.1158/1078-0432.22454580.v1
Autor:
Helen Rizos, Georgina V. Long, Richard F. Kefford, Richard A. Scolyer, Adnan M. Nagrial, Mal Irvine, Suzanah C. Boyd, Jason R. Todd, Hamideh Shahheydari, Carina Fung, Matteo S. Carlino
Supplementary Tables 1-5. S1 In silico evaluation of MEK1 Proline124 variants; S2 Correlation of factors and MEK1 mutation status; S3. Predictors of response to BRAF inhibition; S4. Univariate progression-free survival (PFS) according to MEK1 status;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::423c2fb6fefd7c59faccace81d0c0948
https://doi.org/10.1158/1078-0432.22454577
https://doi.org/10.1158/1078-0432.22454577
Autor:
Helen Rizos, Georgina V. Long, Richard F. Kefford, Richard A. Scolyer, Adnan M. Nagrial, Mal Irvine, Suzanah C. Boyd, Jason R. Todd, Hamideh Shahheydari, Carina Fung, Matteo S. Carlino
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a3623a9533a18ecfd0accdd3f57b114
https://doi.org/10.1158/1078-0432.22454586.v1
https://doi.org/10.1158/1078-0432.22454586.v1
Autor:
Richard A. Scolyer, Adnan Nagrial, Georgina V. Long, Hamideh Shahheydari, Carina Fung, Suzanah C. Boyd, Jason R. Todd, Mal Irvine, Helen Rizos, Richard F. Kefford, Matteo S. Carlino
Publikováno v:
Clinical Cancer Research. 21:98-105
Background: MEK1 mutations in melanoma can confer resistance to BRAF inhibitors, although preexisting MEK1P124 mutations do not preclude clinical responses. We sought to determine whether recurrent, preexisting MEK1P124 mutations affected clinical ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fedeced8ccc5cd9e35838402cb222067
https://doi.org/10.1158/1078-0432.ccr-14-0759
https://doi.org/10.1158/1078-0432.ccr-14-0759
Publikováno v:
Oncoscience
Mutations activating the receptor tyrosine kinase c-Kit occur commonly in melanomas arising on mucosal membranes and acral skin. Clinical studies have demonstrated that selective inhibition of c-Kit is effective in treating patients with c-Kit mutant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::612d158346ec8bf9fe28f3f68db9e1c7
http://europepmc.org/articles/PMC4284619
http://europepmc.org/articles/PMC4284619
Autor:
Peter Hersey, Richard F. Kefford, Carina Fung, Georgina V. Long, Matteo S. Carlino, Stephanie Snoyman, Helen Rizos, Branka Mijatov, Gulietta M. Pupo, Kavitha Gowrishankar, Jason R. Todd
Publikováno v:
Molecular oncology. 8(3)
Acquired resistance to BRAF inhibitors often involves MAPK re-activation, yet the MEK inhibitor trametinib showed minimal clinical activity in melanoma patients that had progressed on BRAF-inhibitor therapy. Selective ERK inhibitors have been propose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7c0235f0e43d90c2dd17f2162f73987
https://pubmed.ncbi.nlm.nih.gov/24476679
https://pubmed.ncbi.nlm.nih.gov/24476679
Publikováno v:
Pigment cellmelanoma research. 26(4)
Activation of the c-Kit receptor tyrosine kinase is rare in melanoma, but occurs in 20-40% of melanoma arising on mucosal membranes, acral skin and skin with chronic sun-induced damage. Many activating c-Kit mutations have been shown to be highly sen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cc5f675f28da334caccb3e1e93f6674
https://pubmed.ncbi.nlm.nih.gov/23582185
https://pubmed.ncbi.nlm.nih.gov/23582185
Publikováno v:
Oncogene. 33(2)
Stimulation of the c-Kit receptor tyrosine kinase has a critical role in the development and migration of melanocytes, and oncogenic c-Kit mutants contribute to the progression of some melanomas. c-Kit signalling activates the mitogen-activated prote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdde8b4e88b67cee716ba466032b2465
https://pubmed.ncbi.nlm.nih.gov/23246970
https://pubmed.ncbi.nlm.nih.gov/23246970